GUEST EDITORIAL  by Friess, Helmut et al.
GUEST EDITORIAL
With its incidence (1011 per 100 000 people) almost
equaling its prevalence in Western countries, pancrea-
tic cancer is one of the most aggressive human tumors.
In the United States alone, 420 000 life years are lost
every year due to this disease. Understanding the
exceptionally aggressive behavior has been the objec-
tive of clinical and basic research elucidating in detail
the molecular changes that lead to the development
and the progression of this disease. The molecular
alterations range from gross chromosomal abnormal-
ities to gene mutations and epigenetic changes, which
act together on the malignant differentiation and
aggressive growth of pancreatic cancer. Clinically,
pancreatic cancer is characterized by retroperitoneal
and perineural infiltration, angio-invasion, high rates
of local relapse after resection, early formation of local
and distant metastases, and resistance to most of the
available treatment regimens, making patient manage-
ment a complex and challenging task.
Surgery: Curative resection is the single most im-
portant factor determining the outcome in patients
with pancreatic cancer. Mortality and morbidity rates
inversely correlate with the number of pancreatic
tumor resections per year. Thus, in high volume
centers, resection-related mortality and morbidity
have substantially decreased over the past decades,
and mortality ratesB/5% have been achieved. In
addition, the long-term survival of patients who
undergo pancreatic resection in high-volume centers
is superior as well, making an even stronger case for
centralization of pancreatic surgery. The pylorus-pre-
serving partial pancreaticoduodenectomy offers long-
term survival, quality of life, and weight gain identical
to those achieved with the classic Whipple procedure.
Extended lymphadenectomy with retroperitoneal
clearance has not resulted in a superior outcome and
should not be performed outside of clinical studies.
Adjuvant therapy: Adjuvant chemotherapy with 5-
fluorouracil (5-FU)/FA according to the ESPAC-1
protocol is the current standard, whereas adjuvant
chemoradiation does not seem to offer a survival
benefit. Nonetheless, encouraging results with an
interferon-based adjuvant chemoradiation protocol
have been reported with a 5-year survival rate of
55%. This study provides hope for a substantial
increase in survival and quality of life following
pancreatic cancer resection, but needs further confir-
mation in well designed randomized controlled trials.
Palliative therapy: In unresectable and/or metastatic
pancreatic cancer, the mainstay therapy is monother-
apy with gemcitabine, despite proven low effectiveness.
So far, classic cytotoxic agents, such as 5-FU, peme-
trexed, irinotecan, exatecan, cisplatin, and others,
given alone or in combination with gemcitabine, have
not proven to be superior. However, current combined
therapy phase III studies with gemcitabine and oxali-
platin or erlotinib (TarcevaTM) seem promising.
Outlook: Recent advances in our understanding of
the molecular behavior of pancreatic cancer and the
subsequent implementation of clinical studies pro-
mise improved 5-year survival rates for at least a
subgroup of patients. For example, several of the
identified molecular alterations of pancreatic cancer
have been studied as possible therapeutic targets. One
of the most promising molecular systems for drug
development is the EGF receptor (EGFR)/ligand
cascade, which triggers not only mitogenic and anti-
apoptotic responses but also cell migration. For
example, the EGFR tyrosine kinase inhibitor gefitinib
(IressaTM) negatively influences pancreatic cancer cell
growth, invasion and colony formation. First results
with blockage of the EGFR by gefitinib, erlotinib, and
cetuximab (ErbituxTM) in phase IIII clinical trials
underline the important role of EGFR signaling in
pancreatic cancer. Further progress will be achieved
by combining new diagnostic markers, surgery, and
chemotherapy/radiotherapy with targeted molecular
and immune therapies. Therefore, a main focus of
academic medicine in the field of pancreatic cancer
will be translational research, transferring advances
from basic research to clinical studies for the benefit
of pancreatic cancer patients.
In this thematic issue of HPB on pancreatic cancer,
leading clinical and basic researchers present the
state-of-the-art in diagnosis, surgery, and therapy of
pancreatic cancer. We believe that this thematic issue
will provide an interesting update and look into the
future for the management of pancreatic cancer.
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